Ross Moat - 16 Mar 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHIEF COMMERCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol: KNSA
Transactions as of: 16 Mar 2025
Net transactions value: +$11,286
Form type: 4
Filing time: 19 Mar 2025, 17:52:26 UTC
Previous filing: 04 Sep 2024
Next filing: 03 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Award	$17,888	+1,118	+5.1%	$16.00	22,854	15 Jan 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Options Exercise		+994	+4.3%		23,848	16 Mar 2025	Direct	F2
transaction	KNSA	Class A Ordinary Share	Tax liability	$6,602	-292	-1.2%	$22.61	23,556	16 Mar 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-994	-100%	$0.000000	0	16 Mar 2025	Class A Ordinary Share	994		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2024 to January 15, 2025. The acquisition of such shares was exempt pursuant to Rule 16b-3(e).
F2	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3	The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021.